RxDoctor Payments Data

Kevin Sorensen, DO

General Practice · Chico, CANPI 1144680141

Payments from drug & device makers

$18,390in general payments, 2019–2025

Across 1,144 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$2K
  • Amgen$2K
  • Pfizer$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AstraZeneca$883
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$18,383100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)258$4,074
Novo Nordisk105$2,040
Amgen100$1,749
Pfizer107$1,319
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC75$1,116
AstraZeneca35$883
Corcept Therapeutics42$817
Boehringer Ingelheim38$620
Lilly USA, LLC46$556
Daiichi Sankyo Inc.27$499
Merck26$415
Biohaven Pharmaceutical Holding Company Ltd.39$414
GSK28$396
Biohaven Pharmaceuticals, Inc.30$260
Eisai Inc.8$260
Johnson & Johnson(2 entities)22$260
Esperion Therapeutics, Inc.15$259
Exact Sciences12$221
Bayer13$184
Amarin Pharma, Inc.11$154
Takeda Pharmaceuticals U.S.A., Inc.10$148
Indivior Inc.5$133
Dexcom, Inc.6$115
Phathom Pharmaceuticals, Inc.5$101
Verity Pharmaceuticals Inc.5$89
Sumitomo Pharma America, Inc.5$89
Vertex3$87
Abbott4$84
Sanofi Pasteur Inc.5$79
Novartis3$72
Pacira Pharmaceuticals Incorporated3$64
Sunovion Pharmaceuticals Inc.8$62
Astellas Pharma US Inc4$54
Aimmune Therapeutics, Inc.3$51
Upsher-smith Laboratories LLC2$47
Boston Scientific2$42
Otsuka America Pharmaceutical, Inc.2$41
E.r. Squibb & Sons, L.L.C.2$39
Pacira Therapeutics, Inc.3$38
Radius Health, Inc.2$37
Axsome Therapeutics, Inc.2$37
Seqirus USA Inc2$37
Teva Pharmaceuticals USA, Inc.2$37
Kowa Pharmaceuticals America, Inc.2$35
Agios Pharmaceuticals, Inc.1$34
Bausch Health US, LLC2$29
Idorsia Pharmaceuticals US Inc2$27
Sanofi-aventis U.S. LLC2$25
Nestle Healthcare Nutrition Inc.1$21
Braintree Laboratories, Inc.1$19
Myovant Sciences Inc.1$19
Tandem Diabetes Care, Inc.1$18
Medtronic1$17
Qiagen, LLC1$15
Cycle Pharmaceuticals Inc1$14
Genentech USA, Inc.1$14
Amneal Pharmaceuticals LLC1$12
Adlon Therapeutics L.p.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,390 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$1,079,661
Medicare patients
1,121
Services billed
45,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin88$120,872
EliquisApixaban84$101,312
MounjaroTirzepatide50$48,975
OzempicSemaglutide38$40,995
FarxigaDapagliflozin Propanediol28$33,585
LinzessLinaclotide23$22,842
Repatha SureclickEvolocumab13$21,272
JanuviaSitagliptin Phosphate17$20,736
ArexvyRsvpref3 Antigen/As01e/Pf66$20,639
TrulicityDulaglutide18$18,749
XareltoRivaroxaban20$18,439
InvokanaCanagliflozin25$17,856
Breo ElliptaFluticasone/Vilanterol26$16,490
ShingrixVaricella-Zoster Ge/As01b/Pf65$14,315
MovantikNaloxegol Oxalate20$12,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$620$120,87288 claims
PfizerEliquis, Paxlovid, Premarin$1,319$112,196155 claims
Lilly USA, LLCMounjaro, Trulicity$556$67,72568 claims
GSKArexvy, Breo Ellipta, Shingrix$396$51,443157 claims
Novo NordiskOzempic$2,040$40,99538 claims
Johnson & JohnsonXarelto, Invokana$260$36,29545 claims
AstraZenecaFarxiga$883$33,58528 claims
AbbVieLinzess, Synthroid$4,074$26,27284 claims
MerckJanuvia$415$20,73617 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$5,926469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →